MyMD Pharmaceuticals, Inc. (MYMD) Stock Analysis

MyMD Pharmaceuticals, Inc. (MYMD) Healthcare & Pipeline Overview

MyMD Pharmaceuticals, Inc. is a clinical-stage biotech firm developing MYMD-1, a TNF-alpha inhibitor targeting chronic inflammation, autoimmune diseases, and aging. The company is also developing Supera-CBD for pain and addiction, positioning it within the competitive biotechnology landscape focused on novel therapeutic platforms.

What Is the Investment Thesis for MYMD?

MyMD Pharmaceuticals presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The core value driver is the successful development and commercialization of MYMD-1, which targets a broad range of indications including chronic inflammation, autoimmune diseases, and aging. Positive clinical trial results for MYMD-1 would likely serve as a significant catalyst, driving substantial valuation increases. The development of Supera-CBD offers a secondary value driver, targeting the pain and addiction markets. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for additional capital. With a market cap of $4.29M and a negative P/E ratio of -0.76, the company's valuation is highly dependent on future clinical and regulatory milestones.

Based on FMP financials and quantitative analysis

MYMD Key Highlights

MYMD-1 is a clinical-stage small molecule designed to regulate the immune system and control TNF-alpha.

• Supera-CBD is a synthetic derivative of cannabidiol being developed for chronic pain, addiction, and epilepsy.
• The company's focus is on developing therapeutic platforms to treat the causes of disease.
• MyMD Pharmaceuticals was founded in 2014 and is headquartered in Baltimore, Maryland.
• The company operates with a small team of 6 employees, led by CEO Ian Rhodes.

Who Are MYMD's Competitors?

MYMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MYMD's Key Strengths?

Novel drug platforms targeting significant unmet medical needs.

• Potential for broad therapeutic applications (autoimmune, aging, pain, addiction).
• Experienced management team with expertise in drug development.
• Strong patent portfolio protecting their intellectual property.

What Are MYMD's Weaknesses?

Clinical-stage company with no approved products.

• Limited financial resources and reliance on external funding.
• Small team size (6 employees).
• High risk of clinical trial failures and regulatory setbacks.

What Could Drive MYMD Stock Higher?

Phase 2 clinical trial results for MYMD-1 in autoimmune diseases.

• Preclinical data release for MYMD-1 in aging and longevity.
• Initiation of Phase 1 clinical trial for Supera-CBD in chronic pain.
• Continued enrollment in ongoing clinical trials.
• Potential partnerships or licensing agreements with pharmaceutical companies.

What Are the Key Risks for MYMD?

Financial-distress signal — its Altman Z-Score of -10.25 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-65.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for MYMD-1 or Supera-CBD.
• Regulatory delays or rejection of drug approval applications.
• Inability to secure additional funding to support clinical development.
• Competition from other companies developing therapies for similar indications.
• Dependence on key personnel and the ability to attract and retain talent.

What Are the Growth Opportunities for MYMD?

• MYMD-1 for Autoimmune Diseases: The autoimmune disease market represents a significant growth opportunity for MyMD Pharmaceuticals. Conditions such as rheumatoid arthritis, psoriasis, and multiple sclerosis affect millions worldwide, creating a substantial unmet need for more effective and targeted therapies. MYMD-1's mechanism of action, which involves regulating the immune system and controlling TNF-alpha, could offer a novel approach to treating these diseases. Positive clinical trial results in this area could lead to partnerships with larger pharmaceutical companies and accelerate the commercialization of MYMD-1. The timeline for this growth opportunity is dependent on the successful completion of ongoing and planned clinical trials.
• MYMD-1 for Aging and Longevity: The potential of MYMD-1 to delay aging and increase longevity represents a longer-term growth opportunity for MyMD Pharmaceuticals. As the global population ages, there is increasing interest in interventions that can promote healthy aging and extend lifespan. While the science in this area is still evolving, MYMD-1's ability to regulate the immune system and control inflammation could have beneficial effects on the aging process. Further research is needed to fully understand the potential of MYMD-1 in this area, but successful preclinical and clinical studies could open up a new market for the company.
• Supera-CBD for Chronic Pain: The market for chronic pain therapies is substantial, driven by the high prevalence of conditions such as back pain, arthritis, and neuropathic pain. Supera-CBD, MyMD Pharmaceuticals' synthetic derivative of cannabidiol, offers a potential alternative to traditional pain medications, which often have significant side effects. The company is positioning Supera-CBD as a non-addictive and effective treatment for chronic pain. Successful clinical trials and regulatory approval could lead to significant market share gains in this area. The timeline for this growth opportunity is dependent on the progress of Supera-CBD through the clinical development pathway.
• Supera-CBD for Addiction: The opioid crisis has highlighted the urgent need for new and effective treatments for addiction. Supera-CBD may have the potential to reduce cravings and withdrawal symptoms in individuals struggling with addiction. The company is exploring the use of Supera-CBD in the treatment of opioid, alcohol, and other substance use disorders. Positive clinical trial results could lead to partnerships with addiction treatment centers and the development of new therapies for this significant public health problem. The timeline for this growth opportunity is dependent on the successful completion of clinical trials and regulatory approval.
• Partnerships and Licensing Agreements: MyMD Pharmaceuticals, as a clinical-stage company, has the opportunity to partner with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could involve licensing agreements, co-development agreements, or outright acquisitions. Partnering with a larger company could provide MyMD Pharmaceuticals with access to additional funding, expertise, and resources, increasing the likelihood of success. The timing of these partnerships is uncertain, but they represent a significant potential growth driver for the company.

What Opportunities Does MYMD Have?

• Partnerships with larger pharmaceutical companies.
• Expansion into new therapeutic areas.
• Positive clinical trial results driving valuation increases.
• Growing market for autoimmune disease and CBD-based therapies.

What Threats Does MYMD Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays in drug approval.
• Patent expiration and generic competition.
• Unfavorable changes in the healthcare landscape.

What Are MYMD's Competitive Advantages?

• Proprietary drug platforms (MYMD-1 and Supera-CBD).
• Patent protection for their drug candidates.
• Expertise in TNF-alpha inhibition and cannabinoid research.
• Potential first-mover advantage in specific therapeutic areas.

What Does MYMD Do?

Founded in 2014 and headquartered in Baltimore, Maryland, MyMD Pharmaceuticals, Inc. is a clinical development stage pharmaceutical company focused on developing therapeutic platforms aimed at addressing the underlying causes of disease. The company's primary focus is on MYMD-1, a drug platform based on a small molecule designed to regulate the immune system by controlling TNF-alpha, a key driver of chronic inflammation, and other pro-inflammatory cytokines. The therapeutic potential of MYMD-1 extends to delaying aging, increasing longevity, and treating autoimmune diseases, as well as COVID-19-associated depression. In addition to MYMD-1, MyMD Pharmaceuticals is also developing Supera-CBD, a synthetic derivative of cannabidiol, targeting chronic pain, addiction, and epilepsy. The company operates within the biotechnology sector, striving to create innovative treatments for significant unmet medical needs. As a clinical-stage company, MyMD Pharmaceuticals is currently navigating the complex regulatory pathways required to bring its drug candidates to market.

What Products and Services Does MYMD Offer?

• Develop MYMD-1, a drug platform targeting TNF-alpha to regulate the immune system.
• Focus on treating chronic inflammation and autoimmune diseases with MYMD-1.
• Research the potential of MYMD-1 to delay aging and increase longevity.
• Develop Supera-CBD, a synthetic derivative of cannabidiol.
• Target chronic pain, addiction, and epilepsy with Supera-CBD.
• Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.

How Does MYMD Make Money?

• Develop and patent novel therapeutic platforms.
• Conduct preclinical and clinical research to validate drug candidates.
• Seek regulatory approval from the FDA and other agencies.
• Potentially partner with larger pharmaceutical companies for commercialization.

What Industry Does MYMD Operate In?

MyMD Pharmaceuticals operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The company's focus on TNF-alpha inhibition places it within the competitive landscape of companies developing therapies for autoimmune and inflammatory diseases. Similarly, the market for CBD-based therapies is experiencing rapid growth, fueled by increasing acceptance and regulatory changes. MyMD Pharmaceuticals competes with both established pharmaceutical companies and other emerging biotech firms in these markets.

Who Are MYMD's Key Customers?

• Patients suffering from chronic inflammatory diseases.
• Individuals with autoimmune disorders.
• People seeking treatments for chronic pain, addiction, and epilepsy.
• Potential pharmaceutical partners interested in licensing or acquiring their drug candidates.

The most recent 10 insider filings for MyMD Pharmaceuticals, Inc. break down as 2 sales and 8 purchases. On net that is roughly 6.1M shares disposed (about $11.4M), a signal worth weighing alongside the fundamentals.

MYMD Valuation & Market Position

With a $4.29M market cap, MyMD Pharmaceuticals, Inc. sits in the micro-cap segment of the market.

Return on equity for MyMD Pharmaceuticals, Inc. stands at -65.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.7%, showing how much profit it generates from its asset base. A current ratio of 3.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -36.6%, the inverse of the P/E and a quick read on earnings relative to price.

MyMD Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.25 places it in the distress zone, a signal of elevated financial risk.

Company Profile

MyMD Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Baltimore, US. The company is led by CEO Ian Rhodes CPA. MYMD has traded publicly since 2014.

MYMD Financials

MYMD Latest News

What Investors Ask About MyMD Pharmaceuticals, Inc. (MYMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources